Savara Inc (SVRA NASDAQ) stock market data APIs
$5.6477
0.22(3.9%)
as of April 10, 2026
Try our APIs with
free plan!
Savara Inc Financial Data Overview
Price chart is built with
Anychart
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.
Prev. Close
5.6477
Open
5.8705
High
5.8733
Low
5.4885
52 wk Range
1.89-7.005
Market Cap
1 158 M
Shares Outstanding
205 M
Revenue
1 000
EPS
-0.13
Beta
0.313
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Savara Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Savara Inc data using free add-ons & libraries
Get Savara Inc Fundamental Data
Savara Inc Fundamental data includes:
- Net Revenue: 1 000
- EBITDA: -122 676 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-26
- EPS/Forecast: -0.1163
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Savara Inc News
New
High Growth Tech Stocks To Watch In The US March 2026
The United States market remained flat over the last week but has risen 16% over the past year, with earnings projected to grow by 16% annually in the coming years. In light of these conditions, ident...
VR Adviser Adds Over 1 Million Savara Shares
According to a filing with the Securities and Exchange Commission dated Feb. 17, VR Adviser, LLC increased its position in Savara(NASDAQ:SVRA) by 1,059,332 shares during the fourth quarter. The fund�...
FDA to review Savara resubmitted Molbreevi BLA
[Headquarters of US Food and Drug Administration (FDA)] Grandbrothers * The U.S. FDA will review Savara's (SVRA [https://seekingalpha.com/symbol/SVRA]) resubmitted BLA for Molbreevi (molgramostim i...
Savara Announces New Employment Inducement Grant
LANGHORNE, Pa., February 13, 2026--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
